Impraz L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance and symptom control. Impraz L Capsule SR is indicated for the treatment of functional dyspepsia, gastroesophageal reflux disease, and other acid-peptic disorders where both acid suppression and enhanced gastric motility are desired. It should be administered under medical supervision with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with hypersensitivity to either component, and potential drug interactions should be monitored. Regular evaluation is recommended to assess therapeutic efficacy and detect any adverse effects.